3-Deazaneplanocin A hydrochlor

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

3-Deazaneplanocin A hydrochloride

CAS No. : 120964-45-6

MCE 国际站：3-Deazaneplanocin A hydrochloride

产品活性：3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) 是一种有效的组蛋白甲基转移酶 (EZH2) 抑制剂。3-Deazaneplanocin A hydrochloride 是一种有效的 S-腺苷同型半胱氨酸水解酶 (AHCY) 抑制剂。

研究领域：Epigenetics

作用靶点：Histone Methyltransferase

In Vitro: 3-Deazaneplanocin A (DZNep) hydrochloride is a potent histone methyltransferase EZH2 inhibitor. Treatment of OCI-AML3 cells with 3-Deazaneplanocin A (1.0 μM) results in a significant increase in accumulation of cells in the G₀/G₁ phase (58.5%) with a concomitant decrease in the number of cells in S phase (35.2%) and G₂/M phases (6.3%) of the cell cycle (P<0.05). Treatment with 3-Deazaneplanocin A (200 nM to 2.0 μM) for 48 hours, dose dependently, inhibits colony growth of OCI-AML3 and HL-60 cells. 3-Deazaneplanocin A (DZNep) hydrochloride reduces the expression of EZH2, especially after 72 hours (e.g. 48%, 32% and 36% reduction of EZH2 in PANC-1, MIA-PaCa-2 and LPc006 cells, respectively). 3-Deazaneplanocin A (DZNep) hydrochloride shows minimal growth inhibition in PANC-1 cells. More than 50% of these cells are still growing after exposure at the highest concentration (20 μM). MIA-PaCa-2 and LPc006 cells are much more sensitive, with IC₀ values of 1.0±0.3 and 0.10±0.03 μM, respectively. 3-Deazaneplanocin A (DZNep) hydrochloride causes dose-dependent inhibition of cell proliferation of NSCLC cell lines, and the IC₀ values range from 0.08 to 0.24 μM.

In Vivo: The survival of NOD/SCID mice with acute myeloid leukemia (AML) due to HL-60 cells is significantly higher, if treated with 3-Deazaneplanocin A (DZNep) and LBH589 (PS) compare to treatment with PS, 3-Deazaneplanocin A, or vehicle alone (P<0.05). Median survival is as follows: control, 36 days; PS, 42 days; 3-Deazaneplanocin A, 43 days; and 3-Deazaneplanocin A plus PS, 52 days. There is a progressive increase in weight of rats treated with physiological saline in a time-dependent manner (the mean growth rate=3.19% per day). Administration of 20 mg/kg 3-Deazaneplanocin A (DZNep) not only markedly reduces the relative weight of the rats compare to the initial weight (−2.0%, −4.9% and −1.2%) in the first three days post-treatment, but also suppresses the weight growth rate to 2.6% per day from the fourth day onwards post-dose.

相关产品：Bioactive Compound Library Plus | Tazemetostat | GSK126 | GSK3326595 | Pinometostat | GSK3368715 dihydrochloride | EPZ015666 | JNJ-64619178 | EED226 | GSK343 | UNC0642 | UNC1999 | Chaetocin | EZM 2302 | BIX-01294 | MS023 | UNC0379 | CM-272 | MM-102 TFA | UNC0638 | SGC0946 | EPZ031686 | LLY-283 | OICR-9429 | EPZ020411 hydrochloride | PFI-2 hydrochloride | A-366 | NSC 663284 | A-196 | UNC0224

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。